These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Oelrich said there was also no reason to split Bayer, whose businesses span agrochemicals, pharmaceuticals and non-prescription drugs. "We function with three very independent businesses," he said.

Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...

However, Bayer's top-selling pharma product Xarelto (rivaroxaban), an anticoagulant, continued to succumb to generic competition with a near-11% fall to €904 million. The solid quarter is ...

Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely off-script. (The Zappos experiment with “Holocracy” memorably comes to mind.

Bayer recently submitted an application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for this third indication for darolutamide in addition ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its ...

AB-1005 has received U.S. FDA Fast Track and UK Medicines and Healthcare products Regulatory Agency ... rigorous assessment and prioritization, Bayer Pharmaceuticals is now fully focused on ...

ZURICH (Reuters) - Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an ...

Ein Jahr später sagte er nun, Bayer strebe keine Pharma- und Biotech-Deals an, deren Volumen zum oberen Rand dieser Spanne hin gehe. Priorität habe stattdessen die Senkung der Schuldenlast.